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Matriptase zymogen supports epithelial
development, homeostasis and regeneration
Stine Friis1,2, Daniel Tadeo1,6, Sylvain M. Le-Gall3,4, Henrik Jessen Jürgensen1, Katiuchia Uzzun Sales1,5,
Eric Camerer3,4 and Thomas H. Bugge1*
Abstract
Background: Matriptase is a membrane serine protease essential for epithelial development, homeostasis, and
regeneration, as well as a central orchestrator of pathogenic pericellular signaling in the context of inflammatory and
proliferative diseases. Matriptase is an unusual protease in that its zymogen displays measurable enzymatic activity.
Results: Here, we used gain and loss of function genetics to investigate the possible biological functions of zymogen
matriptase. Unexpectedly, transgenic mice mis-expressing a zymogen-locked version of matriptase in the epidermis
displayed pathologies previously reported for transgenic mice mis-expressing wildtype epidermal matriptase. Equally
surprising, mice engineered to express only zymogen-locked endogenous matriptase, unlike matriptase null mice,
were viable, developed epithelial barrier function, and regenerated the injured epithelium. Compatible with these
observations, wildtype and zymogen-locked matriptase were equipotent activators of PAR-2 inflammatory signaling.
Conclusion: The study demonstrates that the matriptase zymogen is biologically active and is capable of executing
developmental and homeostatic functions of the protease.
Keywords: Development, Cell surface proteolysis, Epithelial cell signaling, Zymogen activity
Background
Trypsin-like serine proteases constitute a large family
of proteolytic enzymes with diverse functions in ver-
tebrate physiology [1, 2]. Common to members of
this family is a conserved catalytic domain, which
contains a Ser-Asp-His catalytic triad in the active
site. All members of this protease family are synthe-
sized as pro-enzymes (zymogens) with an N-terminal
extension that spatially distorts the active site to ren-
der the protease catalytically inactive. Conversion to
the active protease (zymogen conversion) occurs by
removal of the N-terminal extension by a single
proteolytic cleavage after an Arg or Lys residue,
which is located within a highly conserved activation
cleavage site. Removal of this N-terminal extension
spatially reorients the catalytic domain to its active
conformation [3, 4].
Matriptase is a membrane-anchored trypsin-like serine
protease that is found in all vertebrates and is expressed
in the epithelium of most tissues [5]. Previous studies
have uncovered essential functions of matriptase in key
aspects of epithelial biology, including epithelial develop-
ment, tight junction formation, fluid secretion, and
regeneration of damaged epithelium [6–13]. Deregulated
matriptase activity has also been linked to growth factor
and inflammatory signaling in the context of cancer and
other diseases [14–26].
Matriptase is a modular, approximately 95-kDa type II
transmembrane protein that consists of a cytoplasmic
N-terminal domain, a signal anchor that serves as a
single-pass transmembrane domain, a sea urchin sperm
protein, enteropeptidase, agrin domain, two complement
C1r/s urchin embryonic growth factor and bone mor-
phogenetic protein-1 domains, four low-density lipo-
protein receptor class A domains, and a C-terminal
trypsin-like serine protease domain [21, 27, 28].
Zymogen conversion of matriptase occurs by hydroly-
sis of a specific Arg614-Val615 bond within the amino
acid sequence RQAR614-VVGG [29–31]. Matriptase
zymogen conversion on the surface of epithelial cells
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is followed by rapid inactivation of the protease by
hepatocyte growth factor activator inhibitor (HAI)-1
and shedding of the protease-inhibitor complex from
the cell surface [32, 33].
Matriptase is unusual among trypsin-like serine pro-
teases in that the zymogen possesses measurable en-
zymatic activity. This was first evidenced by the
ability of the purified soluble matriptase serine prote-
ase domain to undergo auto-activation when incu-
bated for prolonged periods [34]. Subsequent studies
showed that the ability of full-length matriptase to
undergo activation site cleavage in cell-based assays
was dependent on the integrity of the matriptase
catalytic triad [30, 35]. A careful biochemical analysis
of a soluble zymogen-locked version of matriptase
comprising the entire ectodomain of the protease
showed that the zymogen displayed 30-fold lower ac-
tivity than the activated form of the enzyme towards
a small peptide substrate that closely resembles the
matriptase activation cleavage site sequence [36]. This
finding led the authors to propose that the principal
function of the enzymatic activity of the matriptase
zymogen is to facilitate matriptase zymogen conver-
sion. On the other hand, using a cell-based assay, we
have recently demonstrated that several zymogen-
locked matriptase mutants, but not a catalytically in-
active matriptase mutant, are capable of activating
prostasin – a validated matriptase substrate [37].
These findings give rise to two hypotheses, namely
that (1) the intrinsic activity of the matriptase zymo-
gen serves exclusively to mediate matriptase zymogen
conversion and that (2) the matriptase zymogen is a
biologically active molecule capable of cleaving
heterologous proteins to execute essential biological
functions of the protein.
In this study, we tested these hypotheses by generating
transgenic mice expressing matriptase active site and
activation cleavage site mutants, and by editing the en-
dogenous matriptase gene (St14). We show that epider-
mal mis-expression of a zymogen-locked, but not a
catalytically inactive, matriptase transgene causes skin
pathology similar to that previously observed in trans-
genic mice expressing wildtype matriptase [14]. Further-
more, we show that, unlike matriptase null mice, mice
engineered to express only zymogen-locked endogenous
matriptase complete development have normal postnatal
survival, develop epithelial barrier function, and are
capable of regenerating damaged epithelium.
Results
Zymogen-locked matriptase is biologically active when
expressed in basal keratinocytes of transgenic mice
We have previously shown that mis-expression of wild-
type matriptase in the basal keratinocyte compartment
of transgenic mice causes alopecia and progressive
interfollicular hyperplasia through the dual activation of
c-met and proteinase activated receptor (PAR)-2 signa-
ling [14, 18, 19]. We used this observation to determine
if zymogen-locked matriptase displays biological activity
in an in vivo setting. Specifically, we generated trans-
genic mice expressing zymogen-locked matriptase by
introducing a R614Q point mutation in the activation
cleavage site, which prevents activation site cleavage re-
quired for formation of the substrate binding pocket and
alignment of the serine-histidine-aspartic acid triad [4].
We also generated transgenic mice expressing catalytic-
ally inactive matriptase by introducing a S805A
mutation, which replaces the serine of the catalytic
serine-histidine-aspartic acid triad. Both matriptase mu-
tants were expressed under the control of a keratin-5
promoter (Fig. 1a), which targets expression of linked
genes to basal keratinocytes of the interfollicular epider-
mis and outer root sheath of hair follicles. Four founders
harboring the K5R614Q transgene were obtained by
pronuclear injection of zygotes. One founder displayed
severe alopecia at the time of weaning and did not trans-
mit the transgene. Two founders had noticeable alopecia
at the time of weaning, and one founder had no notice-
able outward phenotype and a phenotype was also not
observed in the F1 offspring. Four founders harboring
the K5S805A transgene were obtained, of which one was
nulliparous. The remaining three founders transmitted
the transgene to the F1 generation. No outwardly
observable phenotype was found in any of the four
founders or in the F1 offspring.
Detailed characterization of one established line har-
boring the R614Q matriptase transgene (K5R614Q) and
one established line harboring the S805A matriptase
transgene (K5S805A) showed that they expressed mRNA
for each of these transgenes in the skin (Fig. 1b, c),
which resulted in a comparable increase in total skin
matriptase mRNA (Fig. 1d). This increase in matriptase
mRNA resulted in a modest (approximately 1.5-fold) in-
crease in total skin matriptase protein in the K5R614Q
transgenic line (Fig. 1e) and in an approximately five-
fold increase in total skin matriptase protein in the
K5S805A transgenic line (Fig. 1f ). As expected,
immunofluorescence staining of skin from newborn and
adult mice showed expression of matriptase in basal
keratinocytes of both transgenic lines, which was not
detectable in wildtype littermate skin (compare Fig. 2a
with b and c, and e with f and g). The specificity of the
staining was demonstrated by the absence of staining of
matriptase-deficient skin (Fig. 2d). The two established
K5R614Q and K5S805A transgenic lines were indistin-
guishable from wildtype mice at birth and for the first
3–6 weeks of life (data not shown). However, the
K5R614Q mice developed alopecia of the dorsal and
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facial skin with a patchy appearance, resulting in areas of
skin largely devoid of pelage hair within 6–12 months
(compare Fig. 2h and i, top panels). The progressive alo-
pecia of K5R614Q mice was associated with markedly
fewer hair follicles (compare Fig. 2h and i, bottom
panels, quantified in k), as also observed in transgenic
mice expressing wildtype matriptase [14]. However,
interfollicular hyperplasia, a phenotype associated with
transgenic expression of wildtype matriptase, was not
observed. In contrast, no phenotype was apparent in
K5S805A mice, even when followed for up to 1 year
(Fig. 2j), despite the identical expression pattern and
higher level of expression of S805A matriptase protein.
Taken together, this shows that zymogen-locked matrip-
tase is endowed with biological activity in vivo, that it
can elicit one of the phenotypes (progressive alopecia)
elicited by wildtype matriptase when mis-expressed in
mouse epidermis, and that the biological activity of
zymogen matriptase likely depends on the integrity of
the catalytic triad.
Engineering mice expressing zymogen-locked
endogenous matriptase
To determine if zymogen-locked matriptase could not
only mediate pathological functions of the protease but
also perform key physiological functions, we next
generated mice expressing only zymogen-locked en-
dogenous matriptase. Specifically, we introduced a
c.1841–1842 GC→ AA di-nucleotide substitution into
exon 16 of the St14 gene by template-guided repair of
a zinc finger nuclease (ZFN)-induced double strand
DNA break in FVB/NJ zygotes (Fig. 3a). This dinucleo-
tide change generated a mutant St14 allele (hereafter
referred to as St14zym) that encodes a matriptase with
Arg614 substituted by Gln, thus rendering the mutant
matriptase refractory to activation site cleavage, as
shown previously [37]. Introduction of the dinucleotide
change was verified by sequencing analysis of DNA
from mice bred to homozygosity for the mutated allele
(Fig. 3b). The two base pair substitutions from GC to
AA resulted in the elimination of a Cac8I restriction
Fig. 1 Generation of keratin-5-matriptase zymogen-locked and keratin-5-matriptase catalytically inactive transgenic mice. a Schematic structure of
the keratin-5-matriptase transgenes. The bovine keratin-5 promoter (K5), rabbit β-globin exons, rabbit β-globin intron B, mouse matriptase cDNA,
and rabbit β-globin polyadenylation signal (Poly A) are shown. b Expression of the keratin-5-matriptase transgenes in mouse skin. RT-PCR analysis
of skin from an established keratin-5-matriptase zymogen (K5R614Q, lanes 1 and 2) transgenic mouse line, two wildtype littermates (WT, lanes 3
and 4), an established keratin-5-matriptase catalytically inactive (K5S805A, lanes 5 and 6) transgenic mouse line, and two wildtype littermates (WT,
lanes 7 and 8). c and d Quantitative real-time PCR analysis with primer pairs specific for transgenic matriptase mRNA (c) or total matriptase mRNA
(d) in skin from newborn wildtype mice (WT, n = 3 mice), keratin-5-matriptase zymogen-locked transgenic (K5R614Q, n = 4 mice) littermates,
wildtype mice (WT, n = 3 mice), and keratin-5-matriptase catalytically inactive transgenic (K5S805A, n = 3 mice) littermates. Horizontal bars are
means of individual values. e Western blot analysis of total matriptase protein in skin from newborn wildtype mice (lanes 1–4) and keratin-5-matriptase
zymogen-locked (K5R614Q, lanes 5–8) littermates. Quantification of band intensity from scanned Western blot from (e) is shown on the right (mean ± SD).
f Western blot analysis of matriptase in skin from newborn wildtype mice (lanes 1–3) and keratin-5-matriptase catalytically inactive (K5S805A, lanes 4–7)
littermates. Matriptase null skin was included as negative control (KO, lane 8). Molecular weight markers are shown on the left. Quantification of band
intensity from scanned Western blot from F is shown on the right (mean ± SD). P values were determined by Student’s t test. Additional file 1: Raw
supporting data
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endonuclease cleavage site and the generation of a
SmlI restriction endonuclease cleavage site, which
allowed for convenient genotyping of mice by PCR
amplification of the mutated region, followed by diges-
tion of the amplified DNA by either Cac8I or SmlI
(Fig. 3c, d). For detection of matriptase protein, we
used a polyclonal antibody raised against human
matriptase, which cross reacts with mouse matriptase
and has been used previously to detect the protease in
intact mouse tissues and in tissue lysates [38]. This
antibody recognizes the matriptase serine protease do-
main, allowing for identification of activated matrip-
tase and matriptase zymogen by SDS/PAGE under
reducing conditions. Preliminary analysis showed that
detection of the serine protease domain of activation
site-cleaved matriptase in mouse tissues using this
antibody by standard SDS/PAGE followed by Western
blot was difficult due to the sensitivity of the antibody.
Likewise, because prostasin is heterogeneously glyco-
sylated and undergoes C-terminal processing, and be-
cause activation site cleavage and reduction of
prostasin leads to the removal of just 12 amino acids
[39], analysis of the state of activation of prostasin
proved difficult using standard techniques. We there-
fore employed the Peggy Sue capillary electrophoresis
system, which separates proteins by size with high
resolution and detects them by immunoassay in a
sensitive and quantitative format [40], to examine the
expression of matriptase and prostasin in the gene-
edited mice. To aid the identification of the various
forms of prostasin, we included in parallel skin from
mice expressing zymogen-locked endogenous prosta-
sin [41]. Analysis of protein extracts from skin, kid-
ney, lungs, and intestine of newborn St14zym/zym mice
Fig. 2 Zymogen-locked matriptase is biologically active when expressed in basal keratinocytes of transgenic mice. Matriptase protein expression in the
skin of newborn wildtype mice (WT) (a), keratin-5-matriptase zymogen-locked transgenic mice (b), keratin-5-matriptase catalytically inactive mice (c),
matriptase null mice (d), adult wildtype mice (e), keratin-5-matriptase zymogen-locked transgenic mice (f), and keratin-5-matriptase catalytically inactive
transgenic mice (g). Scale bar = 50 μm, representative for a–g. h–j Outward appearance (top panels) and histological appearance (bottom panels, h and e)
of 1-year-old wildtype (h), keratin-5-matriptase zymogen-locked (i), and keratin-5-matriptase catalytically inactive (j) mice. Scale bar = 500 μm, representative
for h–j. k Quantification of number of hair follicles/mm in full skin sections stained with hematoxylin and eosin from wildtype (WT, n = 4 mice),
keratin-5-matriptase zymogen-locked transgenic (K5R614Q, n = 6 mice), and keratin-5-matriptase catalytically inactive transgenic (K5S805A, n = 7 mice)
mice (mean ± SD). Expression of zymogen-locked matriptase, but not catalytically inactive matriptase in basal keratinocytes causes alopecia (top panels)
associated with reduced hair follicle density. Additional file 1: Raw supporting data
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and wildtype (St14+/+) littermates showed that the
mutant matriptase was expressed at levels similar to
wildtype matriptase (Fig. 4a–d, top panels, black
arrow, compare lanes 1 and 2 with 3 and 4). As ex-
pected, whereas matriptase from St14+/+ mice pre-
sented in these tissues as a dominant 95 kDa band
corresponding to zymogen matriptase, and a much
less abundant 30 kDa band corresponding to activated
matriptase [42], only the matriptase zymogen was
found in tissues from St14zym/zym mice (Fig. 4a–d, top
panels, white arrow, compare lanes 1 and 2 with
lanes 3 and 4). Antibody specificity was demonstrated
by the absence of these two immunoreactive proteins
in the same tissues from St14–/– mice analyzed in
parallel (Fig. 4a–d, lanes 5). The same protein ex-
tracts were next analyzed for the expression of pros-
tasin (Fig. 4a–d, middle panels). Interestingly,
prostasin was found in its activation site-cleaved form
in the epidermis of both St14zym/zym mice and St14+/+
mice (Fig. 4a, middle panel, left, white arrow, com-
pare lanes 1–2 to lanes 3–4), but not in St14–/– mice
(lanes 5), as previously shown [42]. Skin lysates from
prostasin null mice (Prss8–/–) and prostasin zymogen-
locked mice (Prss8zym/zym) were used as controls
(Fig. 4a, middle panel, lanes 6 and 7, respectively).
Quantitative analysis of skin extracts (Fig. 4e, f )
showed that the ratio of activated prostasin to prosta-
sin zymogen was reduced by 48% in newborn
St14zym/zym mice as compared to St14+/+ mice,
whereas active prostasin was undetectable in newborn
St14–/– epidermis. A similar analysis of kidney, lung,
and intestine was inconclusive as to the ratio of acti-
vated prostasin to prostasin zymogen in these tissues
due to insufficient chromatographic separation of the
various immunoreactive protein species (Fig. 4b–d,
middle panels and data not shown).
Fig. 3 Generation of mice expressing zymogen-locked endogenous matriptase by ZFN-mediated gene editing. a Structure of donor DNA
(top), wildtype St14 allele with the ZFN binding site (middle), and edited St14 allele (bottom) containing the base pair substitutions of interest.
Exons are indicated as gray boxes and introns as black lines. The highlighted part of the donor DNA shows the dinucleotide substitution
(indicated in red letters and underlined), the ZFN binding site (blue letters), and the synonymous nucleotide changes of the donor DNA
(red letters) to avoid ZFN cleavage of the donor DNA. The ZFN binding site is shown below in capital letters with the ZFN cleavage site in red.
Introduction of the donor DNA at the ZFN target site results in a c.1841–1842 GC→ AA dinucleotide substitution. b Sequence analysis of exon
16 from St14+/+ (top panel) and St14zym/zym (bottom panel) mice confirms the GC→ AA dinucleotide substitution causing the arginine 614 to
glutamine substitution in endogenous matriptase (indicated by red letters in nucleotide and amino acid sequence). c and d Genotyping of
St14zym/zym mice. c The GC→ AA dinucleotide substitution in endogenous St14 gene causes the loss of a Cac8I restriction endonuclease cleav-
age site and the generation of a SmlI restriction endonuclease cleavage site. d PCR amplification of genomic DNA from the targeted St14 exon
14 region from St14+/+ (lanes 2 and 6), St14zym/zym (lanes 3 and 7), and St14zym/+ (lanes 4 and 8) mice. The amplified DNA was digested with
SmlI in lanes 2–4 and with Cac8I in lanes 6–8. Position of molecular weight markers (lanes 1 and 5) are indicated on the left (bp)
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Zymogen-locked matriptase supports epithelial
development, homeostasis, and regeneration
Congenital or conditional matriptase deficiency causes
embryonic or postnatal lethality in mice due to the cata-
strophic loss of barrier function of both simple and
multi-layered epithelium [6, 7, 9, 11, 43]. To determine
if zymogen-locked matriptase can support epithelial de-
velopment and homeostasis, we next interbred St14+/zym
mice and genotyped 93 offspring from a total of 14 lit-
ters. Surprisingly, the epidermis of newborn St14zym/zym
Fig. 4 Zymogen-locked matriptase induces epidermal prostasin processing. Protein extracts from skin (a), kidney (b), lung (c), and intestine (d) from
newborn St14zym/zym (lanes 1 and 2), St14+/+ (lanes 3 and 4), and St14–/– (lane 5) littermates were separated by capillary electrophoresis and probed with
antibodies against matriptase (top panels), prostasin (middle panels), or β-actin (bottom panels). Lanes 6 and 7 in (a) are skin extracts from prostasin null
(Prss8–/–) and prostasin zymogen-locked (Prss8zym/zym) mice, respectively. Zymogens of matriptase and prostasin are indicated with filled arrows, and the
activated forms are indicated with open arrows. n.s. non-specific. Positions of molecular weight markers (kDa) are indicated on the left. e Representative
example of quantification of activated prostasin (open arrow) and zymogen prostasin (filled arrows) in protein extracts from skin from a newborn St14zym/
zym mouse (top panel), St14+/+ mouse (second panel from top), and a newborn St14–/– mouse (second panel from bottom). Skin extracts from a newborn
mouse expressing zymogen-locked (Prss8zym/zym) endogenous prostasin is included as reference (bottom panel). f Ratio of activated prostasin to total
prostasin in skin extracts from newborn St14zym/zym (left bar, n = 7), St14+/+ (middle bar, n = 7), and St14–/– (right bar, n = 2) mice, quantified as in (e). Data
are shown as mean ± SD. *P= 0.0011 was determined by one-way ANOVA, two-tailed. Additional file 1: Raw supporting data
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pups was outwardly indistinguishable from St14+/+ litter-
mates (Fig. 5a), and the body weight of newborn
St14zym/zym pups was not significantly different from
their St14+/zym and St14 littermates (Fig. 5b). Further-
more, St14zym/zym pups were present at weaning at the
expected Mendelian frequency (Fig. 5c). These unex-
pected findings indicate that matriptase can support
postnatal development independent of zymogen
conversion. Newborn St14zym/zym skin presented histo-
logically with a mildly compacted, slightly more
Fig. 5 (See legend on next page.)
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immature stratum corneum (compare Fig. 5d and e,
quantified in j), and was different from the immature
compacted stratum corneum of St14–/– pups (compare
Fig. 5d and f, quantified in k). Epidermal thickness
(excluding stratum corneum) was reduced in both
newborn St14zym/zym epidermis and St14–/– epidermis
(quantified in Fig. 5l and m). The expression pattern of
zymogen matriptase in skin of newborn mice was indis-
tinguishable from that of wildtype littermates (Fig. 5,
compare g and h). Note, however, that antibody sensitiv-
ity allowed for detection of matriptase in hair follicles,
but not for detection of interfollicular suprabasal matrip-
tase documented in previous studies [16, 44]. Skin from
matriptase null mice was included as a negative control
(Fig. 5i). Direct analysis of transepidermal fluid loss rates
revealed only a minimal increase in newborn St14zym/zym
pups (0.51% of body weight per hour), as compared to
St14zym/+ (0.37% of body weight per hour) and St14+/+
littermates (0.36% of body weight per hour) (Fig. 5n),
which was much lower than the fluid loss rates previ-
ously observed in St14–/– pups (2.09% of body weight
per hour) [6, 7].
Congenital or conditional deletion of matriptase
from intestinal epithelial cells of mice causes a cata-
strophic increase in intestinal barrier permeability,
gross disruption of intestinal tissue architecture, failure
to thrive, and high mortality [9]. In sharp contrast,
intestinal tissues from adult St14zym/zym mice were
histologically unremarkable (Fig. 6, compare a to b and
c to d). The expression pattern of zymogen matriptase
in the epithelial cells of the intestines was indistin-
guishable from that of wildtype littermates (Fig. 6,
compare e to f and g to h). Direct measurement of bar-
rier permeability in adult St14zym/zym intestine, as de-
termined by the rate of gavaged FITC-dextran entering
the blood stream (Fig. 6i), was approximately doubled,
as compared to St14zym/+ and St14+/+ littermates
(median 8600 fluorescence units, as opposed to 3700
fluorescence units and 3900 fluorescence units,
respectively), which is a much lower rate than the pre-
viously reported 10-fold increase in barrier permeabil-
ity of St14–/– intestine [9]. This finding shows that
zymogen-locked matriptase can partially fulfill the role
of wildtype matriptase in intestinal barrier
homeostasis.
We recently reported that normal skin wound healing
requires prostasin proteolytic activity, as evidenced by
delayed wound healing in mice expressing catalytically
inactive prostasin [45]. To determine if zymogen-locked
matriptase could support this prostasin-dependent re-
pair process, we next generated 1.5-cm full-thickness in-
cisional skin wounds in the mid-scapular dorsal region
of St14zym/zym mice and their St14zym/+ and St14+/+ lit-
termates. The wounds were left unsutured and un-
dressed and were observed daily by an investigator
blinded as to mouse genotype. The wounds were scored
as healed based on the macroscopic closure of the inci-
sion interface and restoration of epithelial covering.
Interestingly, mice expressing zymogen-locked matrip-
tase were capable of healing their wounds within the
same time frame as their wildtype littermates (Fig. 6j).
Abnormal hair follicle development in mice expressing
zymogen-locked endogenous matriptase
Matriptase is critical for development and maintenance
of the hair follicle compartment of mice, as shown by
congenital [6, 7] and conditional [9] matriptase ablation,
respectively. The fur of adult St14zym/zym mice was unre-
markable (Fig. 7a). However, pelage hair eruption was
slightly delayed in St14zym/zym pups, as revealed through
side-by-side comparison of St14zym/zym pups and wild-
type littermates at days 4–6 (Fig. 7b). Likewise, whiskers,
which are present in wildtype mice at birth, were absent
in newborn St14zym/zym pups (Fig. 7c, Day 0). When they
erupted later in postnatal development, the whiskers
were often kinked and curly (Fig. 7c, Day 4, Day 10, and
6 weeks).
(See figure on previous page.)
Fig. 5 Zymogen-locked endogenous matriptase supports interfollicular epidermal development and epidermal barrier acquisition. a Outward
appearance of newborn St14zym/zym (left) and St14+/+ (right) pups. b Body weights of newborn St14+/+ (left bar, n = 3), St14zym/+ (middle bar, n = 13),
and St14zym/+ (right bar, n = 7) pups. Data are shown as mean ± SD. P = non-significant. One-way ANOVA, two-tailed. c Normal postnatal survival of
mice expressing zymogen-locked endogenous matriptase. Genotype distribution of offspring from interbred St14zym/+ mice. Genotypes were obtained
at weaning from 93 offspring from 14 litters. Hematoxylin and eosin staining (d–f) and matriptase immunohistochemistry (g–i) of skin from newborn
St14zym/zym pups (d and g) and wildtype littermates (e and h). Skin from newborn St14–/– mice was included as comparison for stratum corneum
morphology (f) and as control for antibody specificity (i). Scale bar in d = 50 μm, representative for d–i. Scale bar in inset in g = 20 μm, representative
for inset in g–i. Quantification of stratum corneum thickness of newborn epidermis of St14+/+ pups (left bar, n = 4) and St14zym/zym littermates (right
bar, n = 4) (j), and of newborn epidermis of St14+/+ pups (left bar, n = 2) and St14–/– littermates (right bar, n = 4) (k). Data are shown as mean ± SD.
Quantification of epidermal thickness of newborn epidermis of St14+/+ pups (left bar, n = 4) and St14zym/zym littermates (right bar, n = 4) (l), and of
newborn epidermis of St14+/+ pups (left bar, n = 2) and St14–/– littermates (right bar, n = 4) (m). Data are shown as mean ± SD. P values were
determined by Student’s t test, two-tailed. n Zymogen-locked matriptase supports epidermal barrier formation. Rate of epidermal fluid loss from
newborn mice was estimated by measuring reduction of body weight as a function of time. The data are expressed as the average percentage of
initial body weight for St14+/+ pups (squares; n = 5), St14zym/+ pups (circles; n = 17), and St14zym/zym (triangles; n = 7) littermates (mean ± SD). Error bars
indicate SD, P < 0.0001 (linear regression analysis, two-tailed). Additional file 1: Raw supporting data
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Membrane-anchored prostasin stimulates PAR-2
activation by zymogen-locked matriptase
To further investigate the ability of zymogen-locked
matriptase to induce the cleavage of substrates, we used
two previously established assays in which the activation
of the established matriptase target substrate, PAR-2, is
measured [46, 47]. PAR-2 is a G-protein-coupled
receptor activated by the proteolytic removal of a short
N-terminal peptide by trypsin-like serine proteases.
Matriptase is a potent activator of PAR-2, and wildtype
prostasin can enhance matriptase-dependent PAR-2 acti-
vation [46]. The first assay is performed in KOLF cells,
which are PAR-1-deficient lung fibroblasts, and takes ad-
vantage of a PAR-2-AP fusion protein from which AP is
released after PAR-2 N-terminal cleavage. In this way,
matriptase activity can be quantified by the measure-
ment of AP release to the medium (Fig. 8a). The second
assay detects the amount of activated PAR-2 through the
induction of transcription of a serum response element-
luciferase reporter plasmid (Fig. 8b, c). Expression of
wildtype prostasin or catalytically inactive prostasin (in
which serine 238 of the catalytic serine-histidine-
aspartate triad was mutated to alanine) in KOLF cells
did not induce PAR-2 cleavage (Fig. 8a, compare bar 1
with bars 2 and 3). Expression of wildtype matriptase,
but not zymogen-locked matriptase, induced PAR-2
cleavage in the absence of prostasin (Fig. 8a, compare
bars 1, 4, and 5). Interestingly, however, zymogen-locked
matriptase induced robust cleavage of PAR-2 when co-
expressed with wildtype (Fig. 8a, compare bars 6 and 1),
but not catalytically inactive (Fig. 8a, compare bars 7
and 1) prostasin. No increase in PAR-2 cleavage was ob-
served when catalytically inactive matriptase was
expressed alone (Fig. 8a, compare bars 1 and 8) or was
co-expressed with wildtype or catalytically inactive pros-
tasin (Fig. 8a, compare bar 1 with bars 9 and 10). Unlike
PAR-2 cleavage in KOLF cells, neither wildtype matrip-
tase nor zymogen-locked matriptase were able to induce
Fig. 6 Zymogen-locked endogenous matriptase supports intestinal barrier formation and epidermal regeneration. Histological appearance (a–e, h) and
matriptase immunohistochemistry (e–h) of large (a, b, e, f) and small (c, d, g, h) intestine of 3-month-old St14zym/zym mice (a, c, e, g) or wildtype
littermates (b, d, f, h). Scale bar in (a) = 20 μm, representative for a–h. Scale bar in inset in (e) = 10 μm, representative for insets in e–h. i Concentration of
FITC-labeled dextran in the blood of 4- to 8-week-old St14zym/zym mice (n = 10), St14zym/+ mice (n = 23), and St14+/+ littermates (n = 14) 3 h after
instillation of FITC-labeled dextran into the stomach by oral gavage. A small, but significant, increase in intestinal permeability was observed in St14zym/zym
mice as compared to littermate St14+ mice. One-way ANOVA, non-parametric, two tailed. j Rate of healing of 1.5-cm incisional skin wounds in St14+
(red, n = 10) mice and St14zym/zym (blue, n = 8) littermates. Wound healing was not significantly delayed in St14zym/zym mice relative to St14+ littermates.
Additional file 1: Raw supporting data
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significant PAR-2-dependent serum response element
activity when expressed alone (Fig. 8b, compare bars 1
and 4 with bar 10). However, both wildtype and
zymogen-locked matriptase induced serum response
element activity when co-expressed with wildtype
(Fig. 8b, compare bar 1 with bar 2 and bar 4 with bar 5),
but not catalytically inactive prostasin (Fig. 8b, compare
bar 1 with bar 3 and bar 4 with 6). The fold induction of
PAR-2 activation was less robust in this assay, possibly
reflecting different levels of endogenously expressed
PAR-2-activating proteases in the two cell types and/or a
high constitutive activity of the serum response element-
luciferase reporter gene. Catalytically inactive matriptase
was unable to induce serum response element activity,
whether expressed alone (Fig. 8b, compare bars 7 and
10) or in the presence of wildtype (Fig. 8b, compare bars
8 and 11) or catalytically inactive (Fig. 8b, compare bars
9 and 12) prostasin. In the absence of co-expressed
matriptase, neither wildtype (Fig. 8b, compare bars 10
and 11) nor catalytically inactive (Fig. 8b, compare bars
10 and 12) prostasin induced serum response element
activity. Similar to wildtype prostasin expressed by trans-
fection, exogenously added soluble prostasin stimulated
serum response element activity induced by wildtype
matriptase (Fig. 8c, compare bars 1 and 2). Interestingly,
however, unlike transfected wildtype prostasin, soluble
prostasin was unable to induce serum response element
activity in the presence of zymogen-locked matriptase
(Fig. 8c, compare bars 3 and 4). Catalytically inactive
matriptase did not induce serum response element activ-
ity when expressed alone (Fig. 8c, compare bars 5 and 7)
or in the presence of soluble prostasin (Fig. 8c, compare
bars 6 and 8), and soluble prostasin by itself did not in-
duce serum response element activity (Fig. 8c, compare
bars 7 and 8). The ability of catalytically active prostasin,
but not catalytically inactive prostasin, to promote
zymogen-locked matriptase-dependent PAR-2 activation
may indicate that prostasin, when activated by zymogen-
locked matriptase, executes the activation site cleavage
of PAR-2 or that the intrinsic activity of the matriptase
zymogen is stimulated more effectively by catalytically
active prostasin. Taken together, these data show that
the matriptase zymogen can induce PAR-2 activation in
the presence of prostasin, and that prostasin must be
catalytically active and membrane-anchored to facilitate
matriptase zymogen activation of PAR-2. The ability of
catalytically active prostasin, but not catalytically inactive
prostasin, to promote zymogen-locked matriptase-
dependent PAR-2 activation may indicate that prostasin,
when activated by zymogen-locked matriptase, executes
Fig. 7 Matriptase zymogen conversion is required for normal whisker and pelage hair development. a Representative examples of the
outward appearance of 1-month-old St14+/+ mice (left) and St14zym/zym littermates (right). b Delayed pelage hair eruption in St14zym/zym
mice. Representative example of two St14zym/zym pups and two wildtype littermates at day 6. c Loss of matriptase zymogen conversion
causes whisker defects. Representative examples of whiskers from St14+/+ (top panels) mice and St14zym/zym (bottom panels) littermates at
birth (0 days), 4 days, 10 days, and 6 weeks. St14zym/zym mice display short, curly, and kinked whiskers
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the activation site cleavage of PAR-2 or that the intrinsic
activity of the matriptase zymogen is stimulated more
effectively by catalytically active prostasin.
Discussion
The matriptase-prostasin system was originally proposed
to be a simple cascade in which matriptase activated
prostasin to execute the biologic functions of the system
[42]. Indeed, phenotypic characterization of mice with
congenital matriptase deficiency [6], conditional matrip-
tase deficiency [9], matriptase hypomorphic mice [48],
mice with congenital prostasin deficiency [43], condi-
tional prostasin deficiency [49], prostasin hypomorphic
mice and rats [50], mice expressing zymogen-locked en-
dogenous prostasin [41], and mice expressing catalytic-
ally inactive prostasin [45] supports that this may indeed
be the case in at least one organ – the hair follicle,
which requires both the expression, zymogen conver-
sion, and full activity of each of the two proteases for
normal function. However, studies of these genetically
modified animals and complementary cell-based studies
have also revealed that the functional interactions be-
tween matriptase and prostasin, as well as their individ-
ual functions in other tissues, are much more complex
and still incompletely understood. Thus, the simple
linearity of the protease cascade was challenged by the
ability of prostasin to efficiently activate matriptase on
the surface of cultured cells [46], and by genetic epistasis
analysis placing prostasin as either upstream [47] or
downstream of matriptase [42, 48], depending on the
specific context. More detailed cell-based analysis has
partially reconciled these contradictory findings by
showing that matriptase and prostasin are capable of
forming a reciprocal zymogen activation complex stimu-
lating the conversion of both the matriptase and the
prostasin zymogens [37]. Even more unexpectedly, many
biological functions of prostasin were recently shown to
be independent of both prostasin zymogen conversion
and prostasin catalytic activity [41, 45], although, para-
doxically, even catalytically inactive prostasin requires
strict developmental regulation by cognate serine prote-
ase inhibitors [43].
The current study uncovers additional complexity of
the matriptase-prostasin system by showing that
matriptase zymogen conversion is dispensable for key
functions of the protease in epithelial development and
function in mice. This capacity of a serine protease
zymogen being able to execute essential proteolytic
functions in vivo in the absence of zymogen conver-
sion is rare, and to our knowledge, has only been
Fig. 8 Matriptase zymogen is an efficient PAR-2 activator in the presence of membrane-anchored prostasin and HAI-1. a KOLF cells were transfected with
plasmids encoding PAR-2-AP fusion protein and HAI-1 in combination with expression vectors for wildtype (lanes 2, 6, and 9) prostasin, catalytically inactive
(S238A, lanes 3, 7, and 10) prostasin, wildtype (lane 4), zymogen-locked matriptase (lanes 5–7), or catalytically inactive matriptase (lanes
8–10). The corresponding empty vectors (EV) for prostasin (lanes 1, 4, 5, and 8) and matriptase (lanes 1–3) were used to ensure that
transfections were performed with the same total amount of DNA. Data are shown as mean ± SD of duplicate transfections of free AP
released to the media after 4 h standardized to the AP remaining on the cells. **P < 0.0001, one-way ANOVA. The data represent four
independent experiments. b HEK293 cells were co-transfected with pSRE-firefly luciferase and pRL-Renilla luciferase reporter plasmids in
combination with expression vectors for PAR-2 and HAI-1 (bars 1–12), wildtype (Mat wt) (bars 1–3), zymogen-locked (MatR614Q)
matriptase (bars 4–6), catalytically inactive (MatS805A) matriptase (bars 7–9), or corresponding EV (bars 10–12) in combination with
wildtype (WT) prostasin (bars 2, 5, 8, and 11), catalytically inactive (S238A) prostasin (bars 3, 6, 9, and 12), or corresponding EV (bars 1, 4,
7, and 10). Data are shown as mean ± SD of the mean of triplicate transfections of firefly luciferase light units/Renilla luciferase light units.
**P < 0.0001, one-way ANOVA analysis. The data are representative of three similar experiments. c Zymogen-locked matriptase activity is
dependent on membrane anchorage of prostasin. HEK293 cells were co-transfected with pSRE-firefly luciferase and pRL-Renilla luciferase
reporter plasmids in combination with expression vectors for PAR-2 (bars 1–8), wildtype (Mat wt) matriptase (bars 1 and 2), zymogen-locked
(MatR614Q) (bar 3 and 4) matriptase, catalytically inactive (MatS805A) matriptase (bars 5 and 6), or corresponding EV (bars 7 and 8) and human
recombinant prostasin (bars 2, 4, 6, and 8) or vehicle (bars 1, 3, 5, and 7). Data are shown as the mean ± SD of triplicate transfections of firefly luciferase
light units/Renilla luciferase light units. *P < 0.0001 and n.s. = not significant, one-way ANOVA. The data are representative of three similar experiments
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unequivocally demonstrated for vampire bat plasmino-
gen activator [51, 52]. In this regard, it is worthwhile
noting that activated matriptase is rapidly inhibited by
HAI-1 in epithelial cells, and the ratio of matriptase
zymogen to activated, inhibitor-free matriptase is likely
to be high [53]. It follows that the majority of available
matriptase proteolytic activity on the cell surface may
well originate from the zymogen, despite its lower rate
of substrate catalysis. In support of this, data presented
in this paper show that zymogen-locked matriptase, in
the presence of HAI-1, which inhibits activated
matriptase but not zymogen-locked matriptase, in-
duces prostasin-dependent PAR-2 activation as effi-
ciently as wildtype matriptase in a cell-based assay.
Aligned with this, we found that zymogen-locked
matriptase retains the ability to stimulate epidermal
prostasin zymogen conversion in vivo, and that mice
expressing zymogen-locked endogenous matriptase re-
tain the ability to regenerate epidermis, a process re-
cently shown to involve prostasin proteolytic activity
[45]. Additional evidence for the engagement of the
matriptase zymogen in cell surface proteolysis is pro-
vided by the curious observation that active site inhibi-
tors of matriptase, including small molecule inhibitors
and an antibody-based inhibitor, were either ineffective
or needed concentrations of inhibitor that were mul-
tiple orders of magnitude higher than the Ki of the in-
hibitor for the activated matriptase serine protease
domain to inhibit matriptase-dependent proteolysis on
the cell surface [15, 54, 55].
It still needs to be shown how the current findings
translate to human matriptase. Like rodent matriptase
([36] and the current study), the human matriptase
zymogen is endowed with considerable enzymatic
activity, as determined by the capacity of the soluble re-
combinant serine protease domain to auto-activate [34],
the capacity of full length human matriptase zymogen to
incorporate an activity-based probe in a cell-based assay
[56], and the dependence of the matriptase catalytic
triad for human matriptase to undergo activation site
cleavage in cell-based assays [30, 35].
In the hair follicle and, likely, the interfollicular epi-
dermis, matriptase and prostasin may co-localize con-
stitutively on the plasma membrane [9, 57]. However,
in most polarized epithelia and epithelial cells, matrip-
tase is confined to the basolateral membrane and pros-
tasin to the apical membrane [9, 10, 32, 58, 59],
although prostasin appears to be required for matrip-
tase zymogen conversion even in polarized epithelia
[47, 60]. It has been proposed that matriptase and
prostasin are brought together in polarized epithelia to
facilitate mutual zymogen conversion only after dis-
ruption of homeostasis and loss of tight junction func-
tion [46]. While this may indeed represent a major
pathway for activation of the matriptase-prostasin sys-
tem during epithelial restoration [61], matriptase and
prostasin are required not only for epithelial restor-
ation, but also for normal homeostatic functions of
many polarized epithelia [9, 10, 12, 62–64]. The
current study, when combined with our recent studies
of mice expressing zymogen-locked and catalytically
inactive endogenous prostasin, now indicate that epi-
thelial homeostasis may be maintained largely inde-
pendent of conversion of either the matriptase
zymogen or the prostasin zymogen. Alternatively, a
polarized epithelium at homeostasis may display low
levels of activated matriptase and prostasin due to the
curious routing of prostasin to the basolateral
membrane prior to its final delivery to the apical
membrane [65].
Conclusions
In summary, using gain and loss of function genetics in
mice, we have found that the matriptase zymogen is a
biologically active molecule that sustains epithelial deve-
lopment and homeostasis, and can cause pathology when
mis-expressed. This finding advances our mechanistic un-
derstanding of matriptase and has important implications
for the development of strategies for therapeutic targeting
of this membrane-anchored protease in inflammatory,
proliferative, and degenerative diseases.
Methods
Animal work
St14–/–, Prss8–/–, and Prss8zym/zym mice have been previ-
ously described [6, 41, 49]. All studies were littermate
controlled to avoid genetic background differences from
confounding data interpretation. Both males and females
were used in the study.
Generation of keratin-5-matriptase zymogen-locked and
catalytically inactive transgenic mice
Keratin-5-matriptase transgenic mice were generated by
performing site-directed mutagenesis on the full-length
3.1-kb mouse matriptase cDNA (GenBank AF042822)
inserted into the pBK5-vector, which contains the 5.2-kb
bovine keratin-5 regulatory sequences, β-globin intron 2,
and 3′-polyadenylation sequences [14], by using the
QuickChange Site Directed Mutagenesis Kit (Stratagene,
La Jolla, CA). Site-directed mutagenesis primers for gener-
ating zymogen-locked matriptase, mutating the arginine
614 to glutamine, were F: 5′-CCTTTACCAAACAGGCT
CAAGTGGTTGGTGGC-3′, R: 5′- GCCACCAAC-
CACTTGAGCCTGTTTGGTAAAGG-3′. Primers for
generating catalytically inactive matriptase, mutating the
serine 805 to alanine, were F: 5′- TCCTGCCAGG
GTGACGCTGGTGGCCCCTTG-3′, R: 5′- CAAGGGG
CCACCAGCGTCACCCTGGCAGGA-3′. The linearized
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vectors were microinjected into the male pronucleus of
FVB/NJ zygotes, which were implanted into pseudopreg-
nant mice. Transgenic lines were established and main-
tained in an FVB/NJ background in the hemizygous state.
The transgenic mice were genotyped by PCR amplification
of genomic DNA extracted from tail biopsies using the
following primers: 5′-CGTGCTGGTTATTGTGCTGT
CT-3′ and 5′-GCTACCCATGGTTTTGGCGGTC-3′
[14], followed by direct sequencing of the amplified DNA.
Generation of matriptase zymogen-locked knock-in mice
A custom ZFN was designed by Sigma Aldrich to cleave
the murine St14 gene encoding matriptase. The ZFN
bound the St14 gene 55 bp downstream from the desired
point of mutation at the sequence 5′-GCCCTGGCA
GGTGAGCCTCCacgccCTGGGCCAGGGCCACTTG-3′
(small letters indicate cleavage site). A 2000 bp DNA
donor fragment identical to the genomic sequence of
mouse St14, except for the desired di-nucleotide substitu-
tion, CGC to CAA, changing arginine 614 to glutamine,
was purchased from Blue Heron Biotech (Bothell, WA)
spanning 1000 bp upstream and 1000 bp downstream
from the desired point mutation. The donor DNA also
contained three synonymous base pair changes (shown in
Fig. 2a) to minimize the cleavage of the donor DNA by
the ZFN. The linearized donor DNA and ZFN mRNA
were microinjected into the male pronucleus of FVB/NJ
zygotes, which were implanted into pseudopregnant mice.
The ensuing founders were screened for the intro-
duction of the desired mutation using the primers
WT F; 5′-CTTTACCAAACAGGCTCGC-3′, MUT F;
5′-CTTTACCAAACAGGCTCAA-3′, R WT +MUT
5′-CCATCACCCTGCTATAGTGC-3′. All founders
positive for the insert were subsequently analyzed by
direct sequencing by using primers located upstream
of the DNA template and downstream of the di-nu-
cleotide substitution to preclude PCR amplification of
randomly inserted donor DNA. Three founders posi-
tive for the mutation were identified, two of which
transmitted the edited St14 allele when mated to Black
Swiss mice. Offspring were genotyped by PCR using
primers 5′-GCACACCCAGTGGAGATCAGA-3′ and
5′-CCAGCCAGTCAGGAGAGATGA-3′, which amp-
lify a 250 bp fragment centered around the dinucleo-
tide substitution. The CGC to CAA mutation results
in the loss of a Cac8I restriction site (GCN NGC)
and the simultaneous generation of a SmlI restriction
site (C TYRA G). For genotyping, 5 μL of PCR
product was digested overnight to completion with
restriction enzymes Cac8I or SmlI.
RT-PCR and quantitative real-time PCR analysis
Total skin RNA from newborn pups was homogenized
using Precellys matrix beads and the Precellys 24 high-
throughput tissue homogenizer (Bertin Technologies,
Miami, FL) and then purified using the RNeasy mini kit
(Qiagen, Hilden, Germany). cDNA was amplified by
reverse transcription, followed by PCR amplification using
the High Capacity cDNA Reverse Transcriptase Kit
(Applied Biosystems, Foster City, CA), as recommended
by the manufacturer. To specifically detect transgenic
keratin-5-matriptase mRNA transcripts, PCR was
performed on cDNA using the matriptase exon 1-specific
primer R; 5′-GCTACCCATGGTTTTGGCGGTC-3′ and
a primer complementary to exon 2 of the rabbit β-globin
gene F; 5′-CACGTGGATCCTGAGAACTTCAG-3′.
Quantitative real-time PCR analysis of matriptase was
performed with SYBR Green PCR Master Mix (Applied
Biosystems) according to the manufacturer’s instructions
using the following primers: Total matriptase, 5′-
AGATCTTTC TGGATGCGTATGAGA-3′ and 5′-
GGACTTCATTGTACAGCAGCTTCA-3′; Transgenic
matriptase, 5′-GCTACCCATGGTTTTGGCGGTC-3′
and 5′-CACGTGGATCCTGAGAACTTCAG-3′ (anneal-
ing temperature 60 °C, denaturation temperature 95 °C,
extension temperature 72 °C, 40 cycles). Matriptase
expression levels were normalized against S15 levels in
each sample and amplified with the primers 5′-TTCCG
CAAGTTCACCTACC-3′ and 5′-CGGGCCGGCCATGC
TTTACG-3′.
Protein extraction from mouse tissue
Tissues were dissected, snap frozen on dry ice, and stored
at −80 °C until homogenization in ice-cold lysis buffer
containing 1% Triton X-100, 0.5% sodium-deoxycholate in
phosphate-buffered saline (PBS) plus Proteinase Inhibitor
Mixture (Sigma) and incubation on ice for 10 min. The
lysates were centrifuged at 20,000 × g for 20 min at 4 °C to
remove the tissue debris, and the supernatant was used
for further analysis. The protein concentration was
measured with the BCA assay (Pierce).
Western blot of skin from K5-matriptase transgenic mice
Samples were mixed with 4 × SDS sample buffer
(NuPAGE, Invitrogen) containing 7% β-mercaptoethanol
and boiled for 10 min. The proteins were separated on
4–12% BisTris NuPage gels and transferred to 0.2-μm
pore size PVDF membranes (Invitrogen) blocked with
5% non-fat dry milk in Tris-buffered saline (TBS) con-
taining 0.05% Tween 20 (TBS-T) for 1 h at room
temperature. The PVDF membranes were probed with
primary antibodies diluted in 1% non-fat dry milk in
TBS-T overnight at 4 °C. Antibodies used for mouse ly-
sates were sheep anti-human matriptase (catalogue no.
AF3946, R&D Systems) and mouse anti-human prosta-
sin (catalogue no. 612173, BD Transduction Laborator-
ies, San Jose, CA). α-tubulin antibodies were used as a
loading control (catalogue no. 9099S, Cell Signaling,
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Beverly, MA). The next day, the membranes were
washed three times for 5 min each in TBS-T and incu-
bated for 1 h with alkaline phosphatase-conjugated sec-
ondary antibodies (Thermo Scientific). After three 5-min
washes with TBS-T, the signal was developed using nitro
blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate
solution (Pierce).
Simple Western size separation of proteins from St14
gene-edited mice
The Peggy Sue capillary electrophoresis system [40]
(Protein Simple, Wallingford, CT, USA) was used to
analyze matriptase and prostasin in lysates from new-
born mice. Briefly, snap frozen skin, kidney, lung or in-
testines from newborn mice were lysed in T-PER lysis
buffer with proteinase and phosphatase inhibitors
(Pierce) as well as the serine protease inhibitor AEBSF
to a final concentration of 0.5 mM (Sigma). The lysates
were spun at 15,000 × g for 15 min at 4 °C and the
supernatant was used for the analysis. A final concentra-
tion of 1 μg total protein per μL of sample was analyzed
with the antibodies, sheep anti-human matriptase
(catalogue no. 3946, R&D Systems), mouse-anti human
prostasin (catalogue no. 612173, BD Transduction
Laboratories), and β-actin as a loading control (catalogue
no. ab6276-100, Abcam) according to the manufacturer’s
instructions for size separation of proteins. Quantitative
analysis of immunoreactive proteins was performed
using the Compass Software, which automatically mea-
sures the luminescence signal as a function of the
amount of protein present in the sample at a certain
molecular mass. The software calculates the area under
the curve as a measure of the amount of protein [40].
Immunohistochemistry
Organs were collected from mice and fixed in 4% para-
formaldehyde in PBS for 24 h, embedded into paraffin,
and sectioned. Tissue sections were cleared with
xylene-substitute (Safe Clear, Fisher Scientific), rehy-
drated in a graded series of alcohols, and boiled in
Reduced pH Retrieval Buffer (Bethyl, Montgomery,
TX) for 20 min for antigen retrieval. The sections were
blocked for 1 h in PBS containing 10% horse serum
and incubated at 4 °C overnight with sheep anti-
human matriptase (catalogue no. AF3946, R&D
Systems). The slides were washed three times in PBS
and incubated at room temperature for 45 min with
secondary antibodies, using Alexa Fluor 594-labeled
donkey anti-sheep (Invitrogen) or a biotin-conjugated
anti-mouse secondary antibody (1:1000, Vector
Laboratories, Burlingame, CA) and a Vectastain ABC
kit (Vector Laboratories) using 3,3-diaminobenzidine
as the substrate (Sigma-Aldrich). The tissue sections
were washed three times for 5 min with PBS and
mounted with VectaShield Hard Set Mounting
Medium (Vector Laboratories).
Measurement of stratum corneum and epidermal
thickness
Epidermal thickness (excluding stratum corneum) and
stratum corneum thickness were measured using the
ScanScope software from Aperio. Measurements were
made in the same 0.5–1 cm segment of dorsal skin and
were calculated by averaging independent measurements
per 100 μm skin specimen.
Transepidermal fluid loss assay
Transepidermal fluid loss assay was performed exactly
as previously described [6, 7].
Intestinal epithelial permeability assay
A 22 mg/mL fluorescein isothiocyanate (FITC)-la-
beled dextran (average 4000 g/mol, Sigma) in PBS
was instilled directly into the stomach of mice at a
volume of 10 μL per g of body weight. Intillations
were made using a 1.5-cm long, bulb-tipped gastric
gavage needle (Roboz, Gaithersburg, MD) attached to
a 1 mL syringe. After 3 h, blood was collected from
the heart of freshly euthanized mice and clotted for
2 h at room temperature. Sera were then isolated via
centrifugation at 800 × g for 10 min at room
temperature, upon which the clear upper phase was
transferred into a new tube. All samples were imme-
diately stored at –80 °C until analysis. For the ana-
lysis, 50 μL of each sample was diluted 1:3 in PBS
(Gibco-Invitrogen, Carlsbad, CA) and dispensed into
a 96-well plate. The concentration of FITC-dextran
was determined by reading the fluorescence at
535 nm after excitation at 485 nm using a Victor3V
spectrophotometer (PerkinElmer, Waltham, MA).
Cutaneous wound repair
Full thickness incisional skin wounds (15 mm) were
made in the interscapular dorsum. Healing was assessed
by daily inspection of wounds by an investigator blinded
to genotype, as described previously [66]. Macroscopic
closure of the incisional interface was evaluated both
visually and by palpation, and the wound was scored as
healed when only a minimal residual defect, which
resolved very slowly with time, was observed.
Cell culture and PAR-2 activation assay
HEK293 cells (ATCC, Manassas, VA) were grown in
DMEM supplemented with 2 mM L-glutamine, 10%
fetal bovine serum, 100 units/mL penicillin, and
100 μg/mL streptomycin (Invitrogen) at 37 °C in an at-
mosphere of 5% CO2. Cells (250,000/well) were plated
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in 24-well poly-L-lysine-coated plates and grown for
24 h. Cells were co-transfected with pSRE-firefly lucif-
erase (50 ng), pRL-Renilla luciferase (20 ng), pcDNA3.1
containing a full-length human protease-activated
receptor (PAR)-2 cDNA (100 ng) (Missouri S&T cDNA
Resource Center), pcDNA3.1 containing human
matriptase (100 ng), matriptase locked in its zymogen
form (R614Q) or catalytically inactive matriptase
(S805A) [37], pcDNA3.1 containing human HAI-1
(100 ng), pIRES2-EGFP human prostasin (100 ng), or
catalytically inactive prostasin (S238A) [37] as indicated
in the individual experiments. Lipofectamine
(Invitrogen) was used as the transfection agent accord-
ing to the manufacturer’s instructions. The pSRE-firefly
luciferase is a luciferase reporter gene under the con-
trol of a multimerized serum-response element. The
transfection medium was changed at 18 and 48 h after
transfection, and the cells were serum-starved
overnight. Cells were lysed and luciferase activity was
determined using the Dual-Luciferase assay kit
(Promega) according to the manufacturer’s instructions.
Luminescence was measured using a Wallac Victor2
1420 multilabel counter (PerkinElmer Life Sciences),
and the serum-response element activity was
determined as the ratio of firefly luciferase to Renilla
luciferase light units.
Cleavage assay of PAR fusion proteins
PAR-1 knockout (F2r–/–) lung fibroblasts (KOLF) [67]
were grown in DMEM supplemented with antibiotics
and 5% fetal bovine serum. Transfections were per-
formed with the TransitLT1 transfection reagent
(Euromedex) in complete medium. The cells were trans-
fected with pcDNA3.1SEAP-PAR2 encoding a secreted
AP-fused PAR-2 protein [24], full-length human matrip-
tase cDNA in the pcDNA3.1 vector, or the mutants
matriptase R614Q and matriptase S805A, in combin-
ation with full-length human prostasin cDNA or the
catalytically inactive mutant prostasin S238A. For all
transfections, pcDNA3.1HAI-1 was included to prohibit
the constitutive activation of PAR-2 activation. Cells
were used for experiments 48 h after transfection to de-
termine the cleavage of the co-transfected substrate
SEAP-PAR2. After washing the monolayer for 1 h with
OptiMEM, cells were incubated for 4 h with vehicle only
and medium was collected (fraction 1). Trypsin (10 nM
for 20 min) was then used to release all surface exposed
SEAP moieties (fraction 2). SEAP hydrolysis of para-
nitrophenyl phosphate in fractions 1 and 2 was assessed
at OD405. The ratio between SEAP hydrolysis in 4 h
(fraction 1) and a trypsin strip (fraction 2) was deter-
mined for all conditions. It was then normalized to the
OD405 ratio of cells co-transfected with the SEAP
protein and empty vector.
Statistics and general methods
All analyses were performed and graphs generated
using the Prism5 software (GraphPad Software Inc.)
For comparison of two samples, Student’s t test was
used. For multiple comparisons, one-way ANOVA
was used with adjustment for multiple comparisons
(non-parametric for the gavage study). Transepidermal
fluid loss rates were analyzed by linear regression and
wound healing by the log-rank test. All tests were
two-tailed. Exact sample sizes (biological replicates)
are indicated for each experiment.
Choice of sample size
Figure 1c–f: Large litters containing similar numbers of
wildtype and transgenic mice were chosen for analysis.
Replicated two times. Figure 2k: Sample size based on
tissue available for analysis; performed one time.
Figures 5b and i, 6i and j: Sample size based on number
of litters available for analysis; performed one time.
Figure 8a–c: Sample size based on variation observed in
prior use of assays [24, 37]; replicated three times.
Inclusion/exclusion criteria
Littermates of transgenic mice and wildtype controls
were included. Mice were not excluded from the study.
Randomization of study
The study compared mice of different genotypes and
cells transfected with different plasmids. Randomization
is not applicable.
Blinding
Blinded as to genotype in Figs. 1k, 4a and i, 6i and j, 7b
and c.
Justification of statistical test
Parametric tests were used when normal distribution
and equal variance could be assumed. Non-parametric
tests had sample sizes of more than 5.
Additional file
Additional file 1: Raw supporting data. (XLSX 5530 kb)
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